Ransom Advisory Ltd Buys Shares of 4,696 Thermo Fisher Scientific Inc. $TMO

Key Points

• Ransom Advisory Ltd has acquired 4,696 shares of Thermo Fisher Scientific Inc. for approximately $2.34 million, making the stock 1.2% of its investment portfolio.
• Insider activity indicates a decrease in ownership, with EVP Gianluca Pettiti and CAO Joseph R. Holmes selling a combined 785 shares worth over $380,000.
• Several analysts have adjusted their price targets on Thermo Fisher shares, with UBS increasing it from $460 to $500 while maintaining a "neutral" rating, and Evercore ISI lowering it from $500 to $480.

Ransom Advisory Ltd purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,696 shares of the medical research company's stock, valued at approximately $2,337,000. Thermo Fisher Scientific accounts for about 1.2% of Ransom Advisory Ltd's investment portfolio, making the stock its 21st biggest holding.

Several other hedge funds have also recently bought and sold shares of the stock. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. IMA Advisory Services Inc. acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $37,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have issued reports on the stock. UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Barclays upped their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $589.38.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $483.80 on Wednesday. The firm has a market capitalization of $182.69 billion, a price-to-earnings ratio of 27.98, a PEG ratio of 2.60 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The business's 50-day moving average price is $463.59 and its 200-day moving average price is $452.20. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the company posted $5.37 EPS. The business's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.